Real-World Effectiveness of Eptinezumab after Treatment with Subcutaneous CGRP Monoclonal Antibodies in Patients with Migraine

被引：0
|
作者：
Casaletto, Emily [1 ]
Yang, Qiu Zi [1 ]
Waters, John [1 ]
Curran, John [1 ]
Lowe, Austin [1 ]
Yuan, Hsiangkuo [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203712
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P12-12.009
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
    Alpuente, Alicia
    Torre-Sune, Anna
    Caronna, Edoardo
    Gine-Cipres, Eulalia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2023, 43 (08)
  • [22] Long-term effectiveness of monoclonal anti-CGRP antibodies in patients with migraine in real life
    Perez Prol, C.
    Espinoza Vinces, C.
    Villino Rodriguez, R.
    Atorrasagasti Villar, A.
    Gimeno Rodriguez, M.
    Benitez Martinez, B.
    Beistegui Sarobe, M.
    Sanchez del Rio, M.
    Irimia Sieira, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [23] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Grazzi, Licia
    Giossi, Riccardo
    Montisano, Danilo Antonio
    Canella, Mattia
    Marcosano, Marilena
    Altamura, Claudia
    Vernieri, Fabrizio
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [24] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Licia Grazzi
    Riccardo Giossi
    Danilo Antonio Montisano
    Mattia Canella
    Marilena Marcosano
    Claudia Altamura
    Fabrizio Vernieri
    The Journal of Headache and Pain, 25
  • [25] CGRP plasma levels in migraine patients before and after CGRP monoclonal antibodies therapy
    Vashchenko, N.
    Uzhakhov, A.
    Bogorodskaya, M.
    Korobkova, D.
    Azimova, J.
    Skorobogatykh, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 86 - 86
  • [26] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49
  • [27] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey
    TOXICON, 2022, 214 : S39 - S40
  • [28] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 74 - 74
  • [29] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    HEADACHE, 2021, 61 : 176 - 177
  • [30] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    FRONTIERS IN NEUROLOGY, 2022, 12
12345